Bioethics, Ltd.
BOTH
$1.25
$0.70127.27%
OTC PK
| 09/30/2024 | 06/30/2024 | 03/31/2024 | 12/31/2023 | 09/30/2023 | |
|---|---|---|---|---|---|
| Revenue | -- | -- | -- | -- | -- |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | -- | -- | -- | -- | -- |
| Cost of Revenue | -- | -- | -- | -- | -- |
| Gross Profit | -- | -- | -- | -- | -- |
| SG&A Expenses | 125.60% | 59.74% | 34.98% | 6.55% | -9.86% |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | 125.60% | 59.74% | 34.98% | 6.55% | -9.86% |
| Operating Income | -125.60% | -59.74% | -34.98% | -6.55% | 9.86% |
| Income Before Tax | -63.92% | -31.08% | -19.03% | -4.18% | 2.61% |
| Income Tax Expenses | -- | -- | -- | -- | -- |
| Earnings from Continuing Operations | -63.92% | -31.08% | -19.03% | -4.18% | 2.61% |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | -63.92% | -31.08% | -19.03% | -4.18% | 2.61% |
| EBIT | -125.60% | -59.74% | -34.98% | -6.55% | 9.86% |
| EBITDA | -- | -- | -- | -- | 82.57% |
| EPS Basic | -64.11% | -31.02% | -18.85% | -4.14% | 2.72% |
| Normalized Basic EPS | -63.50% | -30.93% | -18.89% | -4.29% | 2.46% |
| EPS Diluted | -64.11% | -31.02% | -18.85% | -4.14% | 2.72% |
| Normalized Diluted EPS | -63.50% | -30.93% | -18.89% | -4.29% | 2.46% |
| Average Basic Shares Outstanding | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
| Average Diluted Shares Outstanding | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |